The Future of Telehealth for Cancer Care

Cancer Policy Roundtable November 19, 2020

Kristen McNiff Landrum



Project Goals

- Obtain direction from cancer patients and survivors about how to maximize the benefits of telemedicine
- 2. Obtain feedback from cancer providers to support, or offer refinements/ counterpoints
- 3. Create resources:
 - Toolkit for oncology practices on how to address patient barriers and increase the effectiveness of telemedicine visits
 - Toolkit for patients and families on how to prepare for telemedicine visits
- Develop and disseminate policy recommendations from a patient perspective, and engage in policy advocacy



Project Methods: Rapid, pragmatic design

- Steering Committee convened with responsibilities including:
 - Refine project approach and findings
 - Rapidly identify diverse focus group members
- Focus group guide developed and tested
- Focus group members recruited
- Six virtual focus groups convened
 - 5 using video, 1 audio only
 - 3-7 participants per focus group
 - Facilitated and recorded
- Themes identified across focus group transcriptions
 - Summary on subsequent slides
- Theme review with Steering Committee
- Structured survey of oncology providers



Main Findings

- Telehealth has filled a critical gap for cancer care services during the Covid-19 pandemic
 - "...the quality of the interaction between the doctor and the patient is not the same...."

 Additional planning is required to ensure that telehealth is maximally beneficial, and to avoid unintended consequences



Top Level Insights

- Oncology clinicians need to plan the visit types and scenarios that they consider appropriate for telehealth
- In-person visits are also needed for relationship building and reassurance
- Clear strategies and communication tools are needed to ensure successful telehealth visits that promote access to quality healthcare rather than exacerbate disparities
- Oncology clinicians need more training and familiarity with their telehealth platforms and better processes to prepare patients and caregivers for these appointments



Top Level Insights (2)

- Patients need more transparency and predictability related to the out-of-pocket costs for telehealth
- Telehealth should be offered and covered to replace some cancer-related care in a way that is based on patient preference, provides access to care team members, reflects carefully planned timing and availability of services related to telehealth, and presents test results in a more timely manner
- Telehealth might be a mechanism to remove barriers and catalyze innovation in cancer care



Provider Recommendations

- Ensure patient agreement that a telehealth visit is acceptable, balancing safety concerns with patient needs, recognizing that some patients prefer in-person visits
- Send a telehealth visit reminder by text, email, or phone call and ensure receipt of reminder
- Complete follow-up by providing a visit summary and scheduling next appointment, if appropriate
- Consider costs of telehealth for patients before making selections about visit types, and provide transparency and predictability for costs, if known
- Strengthen your video bedside manner



Summary: Future Potential

- Telehealth should be offered and covered to replace some cancer-related health care
 - Based on patient preference
 - Offering access to care team members, not only oncologists/APPs
 - Timing and availability of services (e.g., tests and scans) related to telemedicine visits must be planned
- Telehealth can be a mechanism to remove barriers and catalyze innovation in cancer care
 - For example, in promoting multidisciplinary care planning; care coordination; second opinions; clinical trial participation; supportive care services; support groups



For Additional Information...

https://canceradvocacy.org/telehealth/



Special Thanks

- Steering Committee
 - Randall Broad, Doris Cardwell, Brad Glassel, Loretta Herring, Susan Leigh, Allison Rosen, Kelly Shanahan, Desiree Walker
- Project Team
 - Shelley Fuld Nasso, Elizabeth Goss, Brittani Harris, Kristen McNiff
- Funding Support: Pfizer

